Aytu BioPharma Total Current Liabilities

Aytu BioPharma (AYTU) currently reports a total current liabilities of $60M as of March 2026. That compares with $71M in the prior-year period — down 15.2% year over year. Use the charts on this page to explore Aytu BioPharma's total current liabilities history and peer comparisons.

Aytu BioPharma's total current liabilities decreased from $71M to $60M — a 15.2% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Aytu BioPharma reported $60M in total current liabilities as of March 2026. That compares with $71M in the prior-year period — down 15.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $60M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Aytu BioPharma, and consider following AYTU for alerts when major investors trade the stock.

Aytu BioPharma is classified in the Healthcare sector. On total current liabilities, it currently shows $60M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AYTU with unrelated industries.